Nexvet Biopharma (NVET) Provides Additional NV-01 Data at Investor Day; Cowen Reiterates Outperform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/5/2026
Go back to Nexvet Biopharma (NVET) Provides Additional NV-01 Data at Investor Day; Cowen Reiterates Outperform
November 24, 2015 5:30 AM EST
DUBLIN, Ireland, Nov. 24, 2015 (GLOBE NEWSWIRE) -- Nexvet Biopharma (Nasdaq: NVET), a veterinary biologics developer, today announced that Dr. Mark Heffernan, Nexvet's Chief Executive Officer, is scheduled to present at the 27th Annual Piper Jaffray Healthcare Conference in New York on Wednesday, December 2nd, at 2:30PM ET.
Dr. Heffernan will provide an overview of Nexvet's pioneering... More
November 24, 2015 5:30 AM EST
DUBLIN, Ireland, Nov. 24, 2015 (GLOBE NEWSWIRE) -- Nexvet Biopharma (Nasdaq: NVET), a veterinary biologics developer, today announced that Dr. Mark Heffernan, Nexvet's Chief Executive Officer, is scheduled to present at the 27th Annual Piper Jaffray Healthcare Conference in New York on Wednesday, December 2nd, at 2:30PM ET.
Dr. Heffernan will provide an overview of Nexvet's pioneering... More
November 23, 2015 6:00 AM EST
ADVISORY, Nov. 23, 2015 (GLOBE NEWSWIRE) --
What:Â Nexvet Biopharma plc (Nasdaq: NVET), a global, clinical-stage, veterinary biologics developer, will visit the Nasdaq MarketSite in Times Square to celebrate the successful completion of a pivotal study for NV-01, its biologic therapy in development for the control of pain associated with osteoarthritis in dogs.
In honor of the occasion, the co-founders of Nexvet, Dr. Mark Heffernan, Chief Executive Officer and Dr. David Gearing, Chief Scientific Officer, will ring the Closing Bell.Â
Where:Â Nasdaq MarketSite 4 Times Square... More
November 23, 2015 6:00 AM EST
ADVISORY, Nov. 23, 2015 (GLOBE NEWSWIRE) --
What:Â Nexvet Biopharma plc (Nasdaq: NVET), a global, clinical-stage, veterinary biologics developer, will visit the Nasdaq MarketSite in Times Square to celebrate the successful completion of a pivotal study for NV-01, its biologic therapy in development for the control of pain associated with osteoarthritis in dogs.
In honor of the occasion, the co-founders of Nexvet, Dr. Mark Heffernan, Chief Executive Officer and Dr. David Gearing, Chief Scientific Officer, will ring the Closing Bell.Â
Where:Â Nasdaq MarketSite 4 Times Square... More
